• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Advanced Magnetics inks university deal

Article

Pharmaceutical developer Advanced Magnetics of Cambridge, MA, has signed a research agreement to develop new nucleoside therapeutic drugs with the University of Minnesota in Minneapolis. Under the deal, Advanced Magnetics over the next three years will

Pharmaceutical developer Advanced Magnetics of Cambridge, MA, has signed a research agreement to develop new nucleoside therapeutic drugs with the University of Minnesota in Minneapolis. Under the deal, Advanced Magnetics over the next three years will sponsor research led by Dr. Carston Wagner to develop drug candidates with anti-viral or anti-tumor characteristics. The deal is part of the company’s plan to diversify from its core MRI contrast agent market (SCAN 3/18/98).

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Detecting PCa Recurrence in African Americans: Can 18F-Flotufolastat Have an Impact?
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.